XTX Topco Ltd Purchases 11,492 Shares of Galapagos NV (NASDAQ:GLPG)

XTX Topco Ltd boosted its position in Galapagos NV (NASDAQ:GLPG - Free Report) by 137.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,833 shares of the biotechnology company's stock after acquiring an additional 11,492 shares during the period. XTX Topco Ltd's holdings in Galapagos were worth $545,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Galapagos in the fourth quarter worth approximately $26,000. GAMMA Investing LLC grew its holdings in Galapagos by 77.4% during the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock worth $61,000 after buying an additional 974 shares in the last quarter. QRG Capital Management Inc. raised its position in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after buying an additional 1,866 shares during the last quarter. American Century Companies Inc. lifted its stake in Galapagos by 5.9% during the 4th quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock valued at $711,000 after acquiring an additional 1,431 shares in the last quarter. Finally, Crossmark Global Holdings Inc. boosted its holdings in Galapagos by 31.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company's stock worth $1,352,000 after acquiring an additional 11,777 shares during the last quarter. Institutional investors and hedge funds own 32.46% of the company's stock.

Galapagos Trading Up 1.2 %

GLPG traded up $0.32 during trading hours on Friday, hitting $26.81. The stock had a trading volume of 184,574 shares, compared to its average volume of 206,073. Galapagos NV has a 1 year low of $22.36 and a 1 year high of $31.23. The company's fifty day simple moving average is $25.38 and its 200 day simple moving average is $26.23.

Galapagos (NASDAQ:GLPG - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The firm had revenue of $97.33 million for the quarter, compared to the consensus estimate of $72.22 million. As a group, research analysts forecast that Galapagos NV will post -1.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. TD Cowen downgraded shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a research report on Thursday, January 9th. Morgan Stanley lowered shares of Galapagos from an "equal weight" rating to an "underweight" rating and reduced their price target for the company from $31.00 to $22.00 in a research report on Friday, February 14th. Finally, Barclays reaffirmed an "underweight" rating on shares of Galapagos in a research report on Thursday, January 23rd. Four equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $25.33.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.